Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
7,113 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03943004 | Trial of DFP-14927 in Advanced Solid Tumors | recruiting | Phase 1 | 30 | Delta-Fly Pharma, Inc.INDUSTRY | 1 | Mar 3, 2025 | clinicaltrials |
| NCT06203106 | NYSCF Scientific Discovery Biobank | recruiting | — | 10,000 | New York Stem Cell Foundation Research InstituteOTHER | 1 | Mar 3, 2025 | clinicaltrials |
| Personalized Models for Cancer Research |
| recruiting |
| — |
| 500 |
| New York Stem Cell Foundation Research InstituteOTHER |
| 1 |
| Mar 3, 2025 |
| clinicaltrials |
| NCT00005095 | Specimen and Data Study for Ovarian Cancer Early Detection and Prevention | recruiting | — | 6,000 | Northwestern UniversityOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT02634645 | TREAT-BE Study (Treatment With Resection and Endoscopic Ablation Techniques for Barrett's Esophagus) | recruiting | — | 5,000 | University of Colorado, DenverOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT06849518 | Study of Longitudinal Plasma PD-L1 Testing With Immunotherapy in Lung Cancer | recruiting | N/A | 30 | Ballad HealthOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT05020860 | Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer(RESPONSE) | recruiting | Phase 2 | 185 | Baylor Breast Care CenterOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT02674100 | American Hepato-Pancreato-Biliary Association (AHPBA) Pancreatic Irreversible Electroporation (IRE) Registry | recruiting | — | 500 | University of LouisvilleOTHER | 6 | Feb 25, 2025 | clinicaltrials |
| NCT04590664 | Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma | recruiting | Phase 1 / Phase 2 | 24 | Emory UniversityOTHER | 1 | Feb 25, 2025 | clinicaltrials |
| NCT03138161 | SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma | recruiting | Phase 1 / Phase 2 | 250 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Feb 24, 2025 | clinicaltrials |
| NCT03886311 | Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma(TNT) | recruiting | Phase 2 | 200 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Feb 24, 2025 | clinicaltrials |
| NCT04535271 | Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Soft Tissue Sarcoma(TAGGED) | recruiting | Phase 2 | 80 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Feb 24, 2025 | clinicaltrials |
| NCT06788639 | A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting | recruiting | — | 300 | Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyINDUSTRY | 1 | Feb 24, 2025 | clinicaltrials |
| NCT06788652 | A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting | recruiting | — | 300 | Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyINDUSTRY | 1 | Feb 24, 2025 | clinicaltrials |
| NCT06794268 | A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing Setting | recruiting | — | 300 | Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyINDUSTRY | 1 | Feb 24, 2025 | clinicaltrials |
| NCT06088888 | TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous Leukemia | recruiting | Phase 1 | 90 | Shenzhen TargetRx Co., Ltd.INDUSTRY | 1 | Feb 21, 2025 | clinicaltrials |
| NCT04990921 | Study of Palliative Radiation Combined with Pembrolizumab in Unresectable Metastatic Stage IV Breast Cancer | recruiting | Phase 2 | 15 | University of LouisvilleOTHER | 1 | Feb 20, 2025 | clinicaltrials |
| NCT06493370 | Intravenous Ascorbate Plus Gemcitabine/Carboplatin: A Novel and Cost-Effective Alternative With Evident Efficacy in Patients With Muscle Invasive Bladder Cancer | recruiting | Phase 2 | 48 | University of Kansas Medical CenterOTHER | 1 | Feb 20, 2025 | clinicaltrials |
| NCT02923011 | Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas | recruiting | Phase 3 | 56 | Matthew BucknorOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT05417932 | A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma(TCR-T) | recruiting | Phase 1 / Phase 2 | 46 | SCG Cell Therapy Pte. Ltd.INDUSTRY | 3 | Feb 18, 2025 | clinicaltrials |
| NCT06000787 | MCT for the Harvard/UCSF ROBIN Center | recruiting | N/A | 47 | Brigham and Women's HospitalOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT06272864 | BostonGene and Exigent Genomic INsight Study(BEGIN) | recruiting | — | 400 | BostonGeneINDUSTRY | 1 | Feb 17, 2025 | clinicaltrials |
| NCT06318507 | The Intestinal Microbiome in Triple Negative Breast Cancer Treated with Immunotherapy(IMPACT) | recruiting | — | 25 | Pennington Biomedical Research CenterOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT06826534 | At-Home Cardiac Rehabilitation for Adolescents at Risk for Heart Failure | recruiting | N/A | 20 | Children's Hospital Los AngelesOTHER | 1 | Feb 14, 2025 | clinicaltrials |
| NCT05669430 | A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies | recruiting | Phase 1 / Phase 2 | 365 | GV20 TherapeuticsINDUSTRY | 1 | Feb 13, 2025 | clinicaltrials |
| NCT06337942 | Deceased Donor Bladder or Combined Kidney-bladder Transplantation: a Phase 0 First-in-human Study | recruiting | N/A | 5 | University of California, Los AngelesOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT05918783 | Padeliporfin VTP Using Robotic Assisted Bronchoscopy in Peripheral Lung Cancer | recruiting | Phase 1 | 36 | Impact Biotech LtdINDUSTRY | 1 | Feb 11, 2025 | clinicaltrials |
| NCT05597345 | Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma | recruiting | Phase 2 | 15 | University of RochesterOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT04992728 | Prostate Assessment with Restriction Spectrum Imaging (RSI) MRI | recruiting | — | 100 | University of California, San DiegoOTHER | 1 | Feb 6, 2025 | clinicaltrials |
| NCT06785441 | Older Men's Decision Making About Active Surveillance for Prostate Cancer - Aim 3: Decision Aid Efficacy Testing | recruiting | — | 180 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 4, 2025 | clinicaltrials |
| NCT04929899 | Bright Ideas - CIN Feasibility Study | recruiting | N/A | 75 | The Hospital for Sick ChildrenOTHER | 2 | Jan 31, 2025 | clinicaltrials |
| NCT05381103 | PSMA-PET to Guide Prostatectomy | recruiting | Phase 2 / Phase 3 | 288 | Five Eleven Pharma, Inc.INDUSTRY | 1 | Jan 31, 2025 | clinicaltrials |
| NCT06436157 | A Pilot Study of Genetic Testing Uptake Through Enhanced Oncology Nurse-Led Intervention(GENESIS) | recruiting | N/A | 60 | University of California, DavisOTHER | 1 | Jan 31, 2025 | clinicaltrials |
| NCT03382158 | International PPB/DICER1 Registry | recruiting | — | 3,400 | Children's Hospitals and Clinics of MinnesotaOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT04872166 | A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer | recruiting | Phase 1 | 112 | Edgewood Oncology Inc.INDUSTRY | 1 | Jan 30, 2025 | clinicaltrials |
| NCT04957511 | Gut Microbiome and Treatment for Gynecological Cancer Patients Receiving Immunotherapy | recruiting | — | 30 | ViomeINDUSTRY | 1 | Jan 29, 2025 | clinicaltrials |
| NCT05451303 | Detection of Oral and Throat Cancers Using OralViome Cancer Testing System | recruiting | — | 475 | ViomeINDUSTRY | 1 | Jan 29, 2025 | clinicaltrials |
| NCT06174428 | Validity of Viome's Oral/throat Cancer Test | recruiting | — | 1,000 | ViomeINDUSTRY | 1 | Jan 29, 2025 | clinicaltrials |
| NCT06620627 | Prospective Collection of Samples to Enable the Development of Natera Screening Assay for Early Cancer Detection(PROCEED-CRC) | recruiting | — | 5,000 | Natera, Inc.INDUSTRY | 1 | Jan 29, 2025 | clinicaltrials |
| NCT06800105 | Dysregulation of Whole-body Metabolism in Ovarian Cancer: A Longitudinal Study | recruiting | — | 10 | University of Tennessee Graduate School of MedicineOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT04262830 | Cardiotoxicity Assessment Through Comprehensive Heart Imaging to Predict Heart Failure(CATCH-HF) | recruiting | — | 150 | Hari NarayanOTHER | 1 | Jan 28, 2025 | clinicaltrials |
| NCT06794645 | Pembrolizumab and Pemetrexed for Progressive Chordoma | recruiting | Phase 2 | 21 | Saint John's Cancer InstituteOTHER | 1 | Jan 27, 2025 | clinicaltrials |
| NCT02253251 | Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment | recruiting | — | 15,000 | MiraKindOTHER | 1 | Jan 23, 2025 | clinicaltrials |
| NCT06782555 | A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab | recruiting | Phase 1 / Phase 2 | 71 | ImmunoGenesisINDUSTRY | 1 | Jan 21, 2025 | clinicaltrials |
| NCT06096272 | Using Augmented Reality to Promote Physical Activity in Children With Cerebral Palsy | recruiting | N/A | 30 | Children's Hospital Los AngelesOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06115135 | A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma | recruiting | Phase 2 | 39 | OncotherapeuticsINDUSTRY | 1 | Jan 16, 2025 | clinicaltrials |
| NCT06225310 | A Trial of Selinexor, Ruxolitinib and Methylprednisolone(KPT-IST-391) | recruiting | Phase 1 | 30 | OncotherapeuticsINDUSTRY | 1 | Jan 16, 2025 | clinicaltrials |
| NCT06582914 | Lynch Syndrome Integrative Epidemiology and Genetics(LINEAGE) | recruiting | — | 5,000 | University of Colorado, DenverOTHER | 1 | Jan 15, 2025 | clinicaltrials |
| NCT05488548 | Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies | recruiting | Phase 1 | 75 | Epigenetix, Inc.INDUSTRY | 1 | Jan 14, 2025 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials